<DOC>
	<DOCNO>NCT00323622</DOCNO>
	<brief_summary>The RTS , S/AS02A vaccine ( GSK 257049 vaccine ) , GSK Biologicals ' candidate Plasmodium falciparum ( P. falciparum ) malaria vaccine develop routine immunization infant child live malaria endemic area . The vaccine would offer protection malaria disease due parasite P. falciparum . The vaccine would also provide protection infection hepatitis B virus ( HBV ) . This phase IIb trial carry follow demonstration efficacy candidate malaria vaccine child Mozambique : , vaccine demonstrate approximately 30 % efficacy clinical episode malaria approximately 58 % efficacy severe malaria disease . In study , child Mozambique ( NCT= NCT00197041 ) followed-up ass safety , immunogenicity efficacy candidate malaria vaccine two year period commence 21 month Dose 1 . This protocol post deal objective &amp; outcome measure extension phase year 2 . During extension study , new subject recruit vaccine administer . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Long-Term Follow-up Children 2-Year Period Confirm Safety Immunogenicity GSK 257049 Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<criteria>Inclusion criterion : Completion Visit 7 , Month 21 104297 ( NCT= NCT00197041 ) . Written inform consent obtain parent ( ) guardian ( ) subject Exclusion criterion : Planned use investigational nonregistered drug vaccine study period . Simultaneous participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>33 Months</minimum_age>
	<maximum_age>69 Months</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>